Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3476384 | 0.70 | HSD11B1 (0.33) | HSD11B1 | |
| SCHEMBL7219338 | 0.69 | MAPT (0.33) | HSD11B1 | |
| SCHEMBL5273291 | 0.60 | ALDH1A1 (0.36) | CPA1 | |
| SCHEMBL20553211 | 0.60 | MAOA (0.39) | HSD11B1 | |
| SCHEMBL27818540 | 0.57 | MAOA (0.38) | HSD11B1 | |
| SCHEMBL8083733 | 0.57 | MAPT (0.37) | HSD11B1 | |
| SCHEMBL8765779 | 0.56 | MC4R (0.37) | HSD11B1 | |
| SCHEMBL7502415 | 0.56 | ALDH1A1 (0.41) | HSD11B1 | |
| SCHEMBL3957536 | 0.55 | — | — | |
| SCHEMBL11622221 | 0.54 | ALDH1A1 (0.42) | CPA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7417021-B2 | Biologically active conjugate of a biopolymer and therapeutic agent | GENZYME CORPORATION (US) | 2008-08-26 | — | — | US | disclosed |
| US-20040209842-A1 | Modification of biopolymers for improved drug delivery | GENZYME CORPORATION (US) | 2004-10-21 | — | — | US | disclosed |
| US-6749865-B2 | BIOLOGICALLY ACTIVE CONJUGATE OF A BIOPOLYMER AND A THERAPEUTIC AGENT JOINED BY A DISULFIDE BOND | GENZYME CORPORATION | 2004-06-15 | — | — | US | disclosed |
| US-20030087877-A1 | Modification of biopolymers for improved drug delivery | CENZYME CORPORATION | 2003-05-08 | — | — | US | disclosed |
| EP-1263472-A2 | MODIFICATION OF BIOPOLYMERS FOR IMPROVED DRUG DELIVERY | GENZYME CORPORATION (US) | 2002-12-11 | — | — | EP | disclosed |
| WO-2001060412-A2 | MODIFICATION OF BIOPOLYMERS FOR IMPROVED DRUG DELIVERY | GENZYME CORPORATION (US) | 2001-08-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040209842-A1 | Modification of biopolymers for improved drug delivery | PTMS, PDIA6, SDCBP | HSD11B1 4282/4885CPA1 1592/4885 |
| US-20030087877-A1 | Modification of biopolymers for improved drug delivery | PTMS, PDIA6, SDCBP | HSD11B1 4282/4885CPA1 1592/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.